J&J (JNJ) unveils that the US FDA has granted Priority Review for subcutaneous amivantamab and hyaluronidase for adults with recurrent or metastatic head and neck squamous cell carcinoma

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.